Plasma adiponectin levels and clinical outcomes among haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 23, Issue 8, 2008, Pages 2619-2628

  Rao, Madhumathi ^a   Li, Lijun ^a   Tighiouart, Hocine ^a   Jaber, Bertrand L ^b   Pereira, Brian J G ^c   Balakrishnan, Vaidyanathapuram S ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b ST ELIZABETH'S MEDICAL CENTER   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adiponectin; Cardiovascular disease; ESRD; Inflammation; Mortality

Indexed keywords

ADIPONECTIN; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; UREA;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

ADIPONECTIN; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; COHORT STUDIES; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; PROSPECTIVE STUDIES; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 48749090928     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn070     Document Type: Article

References (36)

1. Chandran M, Philips S, Ciaraldi T et al. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003; 26: 2442-2450
2. Zoccali C, Mallamaci F, Tripepi G et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-141
3. Mallamaci F, Zoccali C, Cuzzola F et al. Adiponectin in essential hypertension. J Nephrol 2002; 15: 507-511
4. Stenvinkel P, Marchlewska A, Pecoits-Filho R et al. Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int 2004; 65: 274-281
5. Foley R. Clinical epidemiology of cardiovascular disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin dial 2003; 16: 111-117
6. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance haemodialysis. N Engl J Med 2002; 347: 2010-2019
7. Greene T, Beck GJ, Gassman JJ et al. Design and statistical issues of the haemodialysis (HEMO) study. Control Clin Trials 2000; 21: 502-525
8. Miskulin DC, Athienites N, Yan G et al. Comorbidity assessment using the index of coexistent diseases in a multicenter clinical trial. Kidney Int 2000; 60: 1498-1510
9. Rao M, Guo D, Jaber BL et al. Transforming growth factor-beta 1 gene polymorphisms and cardiovascular disease in haemodialysis patients. Kidney Int 2004; 66: 419-427
10. Kalantar-Zadeh K. Recent advances in understanding the malnutrition-inflammation-cachexia syndrome in chronic kidney disease patients: what is next? Semin Dial 2005; 18: 365-369
11. Matsushita K, Yatsuya H, Tamakoshi K et al. Comparison of circulating adiponectin and proinflammatory markers regarding their association with metabolic syndrome in Japanese men. Arterioscler Thromb Vasc Biol 2006; 26: 871-876
12. Duncan BB, Schmidt MI, Pankow JS et al. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2004; 53: 2473-2478
13. Maahs DM, Ogden LG, Kinney GL et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 2005; 111: 747-753
14. Pischon T, Girman CJ, Hotamisligil GS et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-1737
15. Schulze MB, Shai I, Rimm EB et al. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005; 54: 534-539
16. Lindsay RS, Resnick HE, Zhu J et al. Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler Thromb Vasc Biol 2005; 25: e15-e16
17. Lawlor DA, Davey Smith G, Ebrahim S et al. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 2005; 90: 5677-5683
18. Kistorp C, Faber J, Galatius S et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005; 112: 1756-1762
19. Cavusoglu E, Ruwende C, Chopra V et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J 2006; 27: 2300-2309
20. Pilz S, Mangge H, Wellnitz B et al. Adiponectin and mortality in patients undergoing coronary angiography. J Clin Endocrinol Metab 2006; 91: 4277-4286
21. Guebre-Egziabher FBJ, Funahashi T, Hadj-Aissa A et al. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant 2005; 20: 129-134
22. Isobe T, Saitoh S, Takagi S et al. Influence of gender, age and renal function on plasma adiponectin level: the Tanno and Sobetsu study. Eur J Endocrinol 2005; 153: 91-98
23. Chudek J, Adamczak M, Karkoszka H et al. Plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc 2003; 35: 2186-2189
24. Diez JJ, Iglesias P, Fernandez-Reyes MJ et al. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol (Oxf) 2005; 62: 242-249
25. Becker B, Kronenberg F, Kielstein JT et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 2005; 16: 1091-1098
26. Tentolouris N, Doulgerakis D, Moyssakis I et al. Plasma adiponectin concentrations in patients with chronic renal failure: relationship with metabolic risk factors and ischemic heart disease. Horm Metab Res 2004; 36: 721-727
27. Menon V, Li L, Wang X et al. Adiponectin and mortality in patients with chronic kidney disease. JASN 2006; 17: 2599-2606
28. Pajvani UB, Hawkins M, Combs TP et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004; 279: 12152-12162
29. Shoji T, Kimoto E, Shinohara K et al. Molecular forms of adiponectin in uraemic plasma. Nephrol Dial Transplant 2004; 19: 1937-1938
30. Pajvani UB, Du X, Combs TP et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 2003; 278: 9073-9085
31. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005; 366: 1279-1289
32. Nissen SE. Perspective: effect of rosiglitazone on cardiovascular outcomes. Curr Cardiol Rep 2007; 9: 343-344
33. Satoh N, Ogawa Y, Usui T et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003; 26: 2493-2499
34. Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome - the heart of the matter. Nephrol Dial Transplant 2002; 17(Suppl 11): 28-31
35. Shoji T, Shinohara K, Hatsuda S et al. Altered relationship between body fat and plasma adiponectin in end-stage renal disease. Metabolism 2005; 54: 330-334
36. Rao M, Guo D, Perianayagam MC et al. Plasma interleukin-6 predicts cardiovascular mortality in haemodialysis patients. Am J Kidney Dis 2005; 45: 324-333